ArQule cuts 25 jobs to extend cash reserves
This article was originally published in Scrip
ArQule cut 25 jobs, trimming its head count by 27.2% and bringing total employment down to 67 people so that the Woburn, Massachusetts-based company can extend the life of its $111.1 million in cash and investments.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.